Report : Asia Pacific Pharma ADMET Testing Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Testing Type (In Vivo ADMET Testing, In Vitro ADMET Testing, and In Silico ADMET Testing), Technology (Cell Culture, High Throughput, Molecular Imaging, and OMICS Technology), and Application (Systemic Toxicity, Renal Toxicity, Hepatotoxicity, Neurotoxicity, and Others)
At 11.1% CAGR, the Asia Pacific pharma ADMET testing market is speculated to be worth US$ 2,978.23 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the Asia Pacific pharma ADMET testing market was valued at US$ 1,586.66 million in 2022 and is expected to reach US$ 2,978.23 million by 2028, registering an annual growth rate of 11.1% from 2022 to 2028. The automation and advancements in ADME testing and the advent of high-throughput screening are the critical factors attributed to the market expansion.
Companies in the pharmaceuticals and biotechnology industries focus on the expansion of their research & development capabilities and drug manufacturing capacity. Rapid developments in computational software, along with the introduction of novel field technologies, are estimated to raise the efficiency of drug development during the forecast period. For instance, toxicity, cytochrome p450 induction, and in vitro metabolism assays, among others, are being incorporated into a single assay on liver hepatocytes. Similarly, 3D cell culture models with multiple tissue cell types are emerging as promising systems. Moreover, microfluidic organ-on-a-chip approaches, such as those commercialized by Emulate, are becoming more mainstream for predictive ADMET studies. ADMET Predictor by Simulations Plus, Inc., ADME/Tox by Sigma-Aldrich, LLC., PhysChem and ADME-Tox Prediction by ACD/Labs, PK/PD Database for Pharmacokinetic Properties by the Laboratory of Computational and Medicinal Chemistry, etc., are several tools developed for predicting toxicity related to ADME. Artificial intelligence (AI) may be used to simulate the ADME of drugs, determine if a medicinal molecule will be effective in humans, and predict safety concerns. During the period of post-COVID recovery, the current popularity and concurrent emergence of AI and machine learning (ML) are likely to have a substantial impact on drug design and development. These technologies have decreased the need for human intervention and raised the quality of life of people as they can be implemented in designing superior-quality healthcare goods. With the help of specialized molecular modeling techniques, such as in-silico simulation, pharmacophore modeling, molecular dynamics, virtual screening, and molecular docking, AI&ML-driven rational drug design seeks to explain the unforeseen bioactivity of natural products most perfectly in a limited timeframe. Additionally, it describes the molecular interaction of drugs and their targets to create more effective drug leads. In January 2022, Charles River Laboratories and Valo Health, LLC, a technology firm leveraging human-centric data and AL-based computing, established a multi-year strategic collaboration to change the drug research & development process. A new revolutionary, AI-enabled drug discovery and development platform will be made available through this partnership by using Charles River's discovery optimization capabilities—including medicinal chemistry, ADME, biology, and pharmacology—and Valo's Opal Platform for small molecule development, which utilizes a "closed-loop" in a silico-experimental platform that rapidly iterates using program data to identify novel compounds. Thus, ADME testing based on automation, AI, and ML, among other technologies, is becoming an important part of the digital health boom, which is providing significant growth opportunities for the Pharma ADMET testing market.
On the contrary, high cost of ADME testing studies hurdles the growth of Asia Pacific pharma ADMET testing market.
- Based on testing type, the Asia Pacific pharma ADMET testing market is segmented into in vivo ADMET testing, in vitro ADMET testing, and in silico ADMET testing. The in vivo ADMET testing segment held 53.6% market share in 2022, amassing US$ 850.91 million. It is projected to garner US$ 1,591.38 million by 2028 to expand at 11.0% CAGR during 2022–2028.
- Based on technology, the Asia Pacific pharma ADMET testing market is segmented into cell culture, high throughput, molecular imaging, and OMICS technology. The cell culture segment held 42.2% market share in 2022, amassing US$ 669.05 million. It is projected to garner US$ 1,265.04 million by 2028 to expand at 11.2% CAGR during 2022–2028.
By the application, the Asia Pacific pharma ADMET testing market is fragmented into systemic toxicity, renal toxicity, hepatotoxicity, neurotoxicity, and others. With 68.8% share of the domain, the systemic toxicity segment dominated the market in 2022. It accrued US$ 1,091.23 million in 2022 and is estimated to generate US$ 2,060.04 million by 2028 to grow at a CAGR of 11.2% over the forecast period.
- Based on country, the Asia Pacific pharma ADMET testing market is categorized into China, Japan, India, Australia, South Korea, and the rest of Asia Pacific. Our regional analysis states that China captured 41.3% market share in 2022. It was assessed at US$ 655.74 million in 2022 and is likely to hit US$ 1,261.13 million by 2028, exhibiting a CAGR of 11.5% during the forecast period.
Key players dominating the Asia Pacific pharma ADMET testing market are Agilent Technologies, Inc.; Bio-Rad Laboratories, Inc.; Biovia (Dassault Systèmes); Charles River Laboratories; MERCK KGaA; Promega Corporation; and Wuxi AppTec among others.
- In Nov 2021, The Coalition for Epidemic Preparedness Innovations (CEPI) and Q2 Solutions, a wholly owned subsidiary of IQVIA and a leading clinical trial laboratory services organization, announced that Q2 Solutions’ facility in Beijing, China, has joined CEPI’s centralized laboratory network. This network is the largest and only global group launched to harmonize the assessment of COVID-19 vaccines currently undergoing preclinical and clinical trials.
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: firstname.lastname@example.org